Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977980 | 1.00 | PKM (0.71) | PKMALDH1A1HTTPOLBMAPT | |
| Bromide SCHEMBL3970603 | 0.98 | PKM (0.69) | PKMALDH1A1HTTPOLBMAPT | |
| SCHEMBL651924 | 0.98 | MAPT (0.69) | PKMALDH1A1HTTPOLBMAPT | |
| SCHEMBL5955341 | 0.98 | MAPT (0.69) | PKMALDH1A1HTTPOLBMAPT | |
| SCHEMBL9122576 | 0.98 | MAPT (0.69) | PKMALDH1A1HTTPOLBMAPT | |
| SCHEMBL8134887 | 0.96 | MAPT (0.67) | PKMALDH1A1HTTPOLBMAPT | |
| Hydrochloric Acid SCHEMBL3244036 | 0.96 | ALDH1A1 (0.67) | PKMALDH1A1HTTPOLBMAPT | |
| SCHEMBL8631891 | 0.96 | MAPT (0.67) | PKMALDH1A1HTTPOLBMAPT | |
| SCHEMBL3419433 | 0.96 | MAPT (0.67) | PKMALDH1A1HTTPOLBMAPT | |
| Propane SCHEMBL8394288 | 0.95 | PKM (0.65) | PKMALDH1A1HTTPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060078503-A1 | 1,4,7,10-Tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them | PLATZEK JOHANNES | 2006-04-13 | — | — | US | disclosed |
| US-6951639-B2 | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them | SCHERING AG (DE) | 2005-10-04 | — | — | US | disclosed |
| US-20020176823-A1 | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2002-11-28 | — | — | US | disclosed |
| US-6399043-B1 | RADIOLABELED MACROCYCLIC GADOLINIUM COMPLEXES WITH SUBSTANTIALLY BETTER NEURAL COMPATIBILITY; ENHANCED SIGNAL INTENSITY FOR NUCLEAR SPIN TOMOGRAPHY; WATER SOLUBILITY AND LOW OSMOLALITY; STABLE; NMR; RADIOIMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-06-04 | — | — | US | disclosed |
| US-5980864-A | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them | SCHERING AKTIENGELLSELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
| EP-0448191-B1 | 1,4,7,10-Tetraazacyclododecane-butyltriols, process for their preparation, and pharmaceutical agents containing these compounds | SCHERING AG (DE) | 1995-06-28 | — | — | EP | disclosed |
| EP-0255471-B1 | 1,4,7,10-TETRAAZACYCLODODECANE-DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-09-09 | — | — | EP | disclosed |
| EP-0448191-A1 | 1,4,7,10-Tetraazacyclododecane-butyltriols, process for their preparation, and pharmaceutical agents containing these compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-09-25 | — | — | EP | disclosed |
| EP-0255471-A1 | 1,4,7,10-Tetraazacyclododecane-derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060078503-A1 | 1,4,7,10-Tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them | UGT2B17, CYP3A7, UGT2B7 | PKM 3682/4885ALDH1A1 747/4885HTT 2351/4885 |
| US-20020176823-A1 | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them | CYP11B1, CYP11B2, BBOX1 | PKM 4092/4885ALDH1A1 505/4885HTT 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.